inclusion criteria: 1. males or female participants ≥ 18 years of age and ≥ 40 kilograms at the time of providing informed consent. 2. confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection (for example, via polymerase chain reaction and/or antibody test) presenting as severe covid-19 requiring hospitalization. 3. severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography or x-ray at screening or within the 3 days prior to screening, as part of the participant's routine clinical care. 4. respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure or bilevel positive airway pressure). 5. female participants of childbearing potential and male participants with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug.

inclusion criteria: 1. males or female participants ≥ 18 years of age and ≥ 40 kilograms at the time of providing informed consent. 2. confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection (for example, via polymerase chain reaction and/or antibody test) presenting as severe covid-19 requiring hospitalization. 3. severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography or x-ray at screening or within the 3 days prior to screening, as part of the participant's routine clinical care. 4. respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure or bilevel positive airway pressure). 5. female participants of childbearing potential and male participants with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug.

inclusion criteria: males or female participants ≥ 18 years of age and ≥ 40 kilograms at the time of providing informed consent. confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection (for example, via polymerase chain reaction and/or antibody test) presenting as severe covid-19 requiring hospitalization. severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography or x-ray at screening or within the 3 days prior to screening, as part of the participant's routine clinical care. respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure or bilevel positive airway pressure). female participants of childbearing potential and male participants with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug.

inclusion criteria: males or female participants ≥ 18 years of age and ≥ 40 kilograms at the time of providing informed consent. confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection (for example, via polymerase chain reaction and/or antibody test) presenting as severe covid-19 requiring hospitalization. severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography or x-ray at screening or within the 3 days prior to screening, as part of the participant's routine clinical care. respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure or bilevel positive airway pressure). female participants of childbearing potential and male participants with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug.

inclusion criteria: males or females ≥ 18 years of age and ≥ 40 kg at the time of providing informed consent confirmed diagnosis of sars-cov-2 infection (eg, via polymerase chain reaction [pcr] and/or antibody test) presenting as severe covid-19 requiring hospitalization severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography (ct) or x-ray at screening or within the 3 days prior to screening, as part of the patient's routine clinical care respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure [cpap] or bilevel positive airway pressure [bipap]) female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug

inclusion criteria: males or females ≥ 18 years of age and ≥ 40 kg at the time of providing informed consent confirmed diagnosis of sars-cov-2 infection (eg, via polymerase chain reaction [pcr] and/or antibody test) presenting as severe covid-19 requiring hospitalization severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography (ct) or x-ray at screening or within the 3 days prior to screening, as part of the patient's routine clinical care respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure [cpap] or bilevel positive airway pressure [bipap]) female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug

inclusion criteria: 1. males or females ≥ 18 years of age and ≥ 40 kg at the time of providing informed consent 2. confirmed diagnosis of sars-cov-2 infection (eg, via polymerase chain reaction [pcr] and/or antibody test) presenting as severe covid-19 requiring hospitalization 3. severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography (ct) or x-ray at screening or within the 3 days prior to screening, as part of the patient's routine clinical care 4. respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure [cpap] or bilevel positive airway pressure [bipap]) 5. female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug

inclusion criteria: 1. males or females ≥ 18 years of age and ≥ 40 kg at the time of providing informed consent 2. confirmed diagnosis of sars-cov-2 infection (eg, via polymerase chain reaction [pcr] and/or antibody test) presenting as severe covid-19 requiring hospitalization 3. severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography (ct) or x-ray at screening or within the 3 days prior to screening, as part of the patient's routine clinical care 4. respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure [cpap] or bilevel positive airway pressure [bipap]) 5. female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug